[go: up one dir, main page]

GR81947B - - Google Patents

Info

Publication number
GR81947B
GR81947B GR66464A GR810166464A GR81947B GR 81947 B GR81947 B GR 81947B GR 66464 A GR66464 A GR 66464A GR 810166464 A GR810166464 A GR 810166464A GR 81947 B GR81947 B GR 81947B
Authority
GR
Greece
Prior art keywords
interferons
host organisms
vectors
viral
expressing
Prior art date
Application number
GR66464A
Other languages
English (en)
Inventor
David Van Norman Goeddel
Original Assignee
Genentech Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US06/237,388 external-priority patent/US4414150A/en
Priority claimed from US06/305,657 external-priority patent/US4456748A/en
Application filed by Genentech Inc filed Critical Genentech Inc
Publication of GR81947B publication Critical patent/GR81947B/el

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/555—Interferons [IFN]
    • C07K14/56—IFN-alpha
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/70—Vectors or expression systems specially adapted for E. coli
    • C12N15/71—Expression systems using regulatory sequences derived from the trp-operon
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Biomedical Technology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Microbiology (AREA)
  • Physics & Mathematics (AREA)
  • Medicinal Chemistry (AREA)
  • Plant Pathology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oncology (AREA)
  • Public Health (AREA)
  • Virology (AREA)
  • Communicable Diseases (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Toxicology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Peptides Or Proteins (AREA)
  • Saccharide Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
GR66464A 1980-11-10 1981-11-09 GR81947B (el)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US20557980A 1980-11-10 1980-11-10
US06/237,388 US4414150A (en) 1980-11-10 1981-02-23 Hybrid human leukocyte interferons
US06/305,657 US4456748A (en) 1981-02-23 1981-09-25 Hybrid human leukocyte interferons

Publications (1)

Publication Number Publication Date
GR81947B true GR81947B (el) 1984-12-12

Family

ID=27394813

Family Applications (1)

Application Number Title Priority Date Filing Date
GR66464A GR81947B (el) 1980-11-10 1981-11-09

Country Status (34)

Country Link
EP (1) EP0051873B1 (el)
JP (1) JP2642291B2 (el)
KR (1) KR920007439B1 (el)
AT (1) ATE46718T1 (el)
AU (1) AU555293B2 (el)
BR (1) BR8107293A (el)
CA (2) CA1212915A (el)
CH (2) CH663032A5 (el)
DE (2) DE3144469A1 (el)
DK (1) DK173590B1 (el)
DO (1) DOP1981004064A (el)
DZ (1) DZ350A1 (el)
ES (2) ES506955A0 (el)
FI (1) FI79550C (el)
FR (1) FR2493867B1 (el)
GB (1) GB2090258B (el)
GR (1) GR81947B (el)
HK (1) HK51685A (el)
IE (1) IE51850B1 (el)
IL (1) IL64243A (el)
IT (1) IT1169276B (el)
KE (1) KE3536A (el)
LU (1) LU83745A1 (el)
MC (1) MC1424A1 (el)
MY (2) MY8700710A (el)
NL (1) NL189092C (el)
NO (1) NO165201C (el)
NZ (1) NZ198906A (el)
PH (1) PH18565A (el)
PL (1) PL233748A1 (el)
PT (1) PT73955B (el)
SE (1) SE460539B (el)
YU (1) YU46597B (el)
ZW (1) ZW26981A1 (el)

Families Citing this family (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CH651308A5 (de) * 1980-07-01 1985-09-13 Hoffmann La Roche Interferone und deren herstellung.
WO1983000693A1 (en) * 1981-08-14 1983-03-03 Berg, Kurt, Frimann SUBJECTS RELATING TO HUMAN INTEFERON-'alpha' SUBTYPE PROTEINS AND CORRESPONDING ANTIBODIES
EP0072541A3 (en) * 1981-08-14 1984-04-18 F. HOFFMANN-LA ROCHE & CO. Aktiengesellschaft Human leukocyte interferons, process for their microbial production, intermediates therefor and compositions containing them
GB2108510B (en) * 1981-10-03 1984-12-12 Ciba Geigy Ag Dnas, recombinant dnas, hosts containing them, polypeptides and processes for the production thereof
EP0098876A1 (en) * 1982-01-19 1984-01-25 Cetus Corporation Multiclass hybrid interferons
DE3220116A1 (de) * 1982-05-28 1983-12-01 Dr. Karl Thomae Gmbh, 7950 Biberach Mikrobiologisch hergestellte (alpha)- und ss-interferone, dna-sequenzen, die fuer diese interferone codieren, mikroorganismen, die diese genetische information enthalten, und verfahren zu ihrer herstellung
IE56509B1 (en) * 1982-11-04 1991-08-28 Univ California Methods for oncogenic detection
DE3490055T1 (de) * 1983-02-24 1985-05-02 Institut bioorganičeskoj chimii imeni M.M. Šemjakina Akademii nauk SSSR, Moskau/Moskva Menschliches Leukozyteninterferon N und Verfahren zu dessen Herstellung in Bakterienzellen
GB8315980D0 (en) * 1983-06-10 1983-07-13 Biogen Nv Producing hybrid dna sequences
GB8317880D0 (en) * 1983-07-01 1983-08-03 Searle & Co Structure and synthesis of interferons
US4892743A (en) * 1983-12-21 1990-01-09 Schering Corporation Novel hybrid interferon species
EP0146903A3 (en) * 1983-12-19 1987-07-22 Schering Corporation Production of a vector encoding a novel hybrid interferon species
DE3409966A1 (de) * 1984-03-19 1985-09-26 Hoechst Ag, 6230 Frankfurt Gentechnologisches verfahren zur herstellung von human-gammainterferon und mittel zur durchfuehrung dieses verfahrens
JPS6156199A (ja) * 1984-08-27 1986-03-20 Shionogi & Co Ltd 新規ヒトインタ−フエロンα類
EP0173935A1 (en) * 1984-08-31 1986-03-12 University Patents, Inc. Hybrid lymphoblastoid-leukocyte human interferons
DE3434345A1 (de) * 1984-09-19 1986-03-27 Hoechst Ag, 6230 Frankfurt Verwendung von (alpha)-interferonen zur bekaempfung von durchfaellen
DE3685044D1 (de) * 1985-02-01 1992-06-04 Ici Plc Analoge interferon-polypeptide, verfahren zu deren herstellung und diese enthaltende pharmazeutische zusammensetzungen.
ATE78262T1 (de) * 1985-06-11 1992-08-15 Ciba Geigy Ag Hybrid-interferone.
EP0240550A4 (en) * 1985-09-26 1989-09-19 Genetics Inst TENSIO-ACTIVE PULMONARY PROTEINS.
US4806347A (en) * 1985-12-11 1989-02-21 Schering Corporation Interferon combinations
EP0490233A1 (de) * 1986-03-10 1992-06-17 BOEHRINGER INGELHEIM INTERNATIONAL GmbH Monoclonale Antikörper gegen BgIII-Hybridinterferone, deren Verwendung und Verfahren zu ihrer Herstellung
DE3607835A1 (de) * 1986-03-10 1987-09-24 Boehringer Ingelheim Int Hybridinterferone, deren verwendung als arzneimittel und als zwischenprodukte zur herstellung von antikoerpern und deren verwendung sowie verfahren zu ihrer herstellung
US4851220A (en) * 1986-11-26 1989-07-25 Schering Corporation Stable oleaginous gel
US4853218A (en) * 1987-02-24 1989-08-01 Schering Corporation Zinc-protamine-alpha interferon complex
EP0331635A3 (en) * 1988-02-29 1990-02-28 The Board of Regents of the University of Texas System Preparations for treating bladder cancer
US5372808A (en) † 1990-10-17 1994-12-13 Amgen Inc. Methods and compositions for the treatment of diseases with consensus interferon while reducing side effect
GB2273931A (en) * 1992-09-28 1994-07-06 Unilever Plc Mutant polypeptides
AU701106B2 (en) 1995-06-07 1999-01-21 Promega Biosciences, Inc. Novel carbamate-based cationic lipids
TW442492B (en) * 1995-07-26 2001-06-23 Novartis Ag Process for the enrichment of interferon
FR2823220B1 (fr) 2001-04-04 2003-12-12 Genodyssee Nouveaux polynucleotides et polypeptides de l'erythropoietine (epo)
WO2004022593A2 (en) 2002-09-09 2004-03-18 Nautilus Biotech Rational evolution of cytokines for higher stability, the cytokines and encoding nucleic acid molecules
US7314613B2 (en) 2002-11-18 2008-01-01 Maxygen, Inc. Interferon-alpha polypeptides and conjugates
BRPI0511196A (pt) 2004-05-19 2007-12-04 Maxygen Inc polipeptìdeo isolado ou recombinante, conjugado, composição, célula hospedeira, vetor, métodos para preparar um polipeptìdeo, para preparar um conjugado, para reduzir o número de cópias de um vìrus em células infectadas com o vìrus, para reduzir o nìvel de rna hcv, dna hbv e rna hiv no soro de um paciente infectado com hcv, hbv e hiv, e, uso do polipeptìdeo, do conjugado ou da composição
US7619067B2 (en) 2005-05-18 2009-11-17 Maxygen, Inc. Evolved interferon-alpha polypeptides

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK170236B1 (da) * 1980-01-08 1995-07-10 Biogen Inc Rekombinante DNA-molekyler, fremgangsmåde til fremstilling af et polypeptid af IFN-alfa typen og fremgangsmåde til udvælgelse af DNA-sekvenser, der koder for polypeptider af IFN-alfa typen

Also Published As

Publication number Publication date
CH663032A5 (de) 1987-11-13
NO165201C (no) 1991-01-16
PT73955B (en) 1983-11-23
KR920007439B1 (ko) 1992-09-01
PL233748A1 (en) 1983-07-18
JP2642291B2 (ja) 1997-08-20
DK173590B1 (da) 2001-04-02
AU7730481A (en) 1982-05-20
LU83745A1 (de) 1983-09-01
CH660743A5 (de) 1987-06-15
ES8304200A1 (es) 1983-03-01
PH18565A (en) 1985-08-09
BR8107293A (pt) 1982-08-03
ES8302778A1 (es) 1983-02-01
KE3536A (en) 1985-06-07
IE51850B1 (en) 1987-04-15
IT1169276B (it) 1987-05-27
FI79550C (fi) 1990-01-10
NL189092B (nl) 1992-08-03
PT73955A (en) 1981-12-01
NO165201B (no) 1990-10-01
NL8105078A (nl) 1982-06-01
AU555293B2 (en) 1986-09-18
NL189092C (nl) 1993-01-04
EP0051873A2 (en) 1982-05-19
ES506955A0 (es) 1983-02-01
ES512354A0 (es) 1983-03-01
CA1212915A (en) 1986-10-21
NZ198906A (en) 1985-12-13
DZ350A1 (fr) 2004-09-13
FI813539L (fi) 1982-05-11
EP0051873A3 (en) 1982-09-22
MY8800066A (en) 1988-12-31
DE3144469A1 (de) 1982-09-02
IE812622L (en) 1982-05-10
JPH07308191A (ja) 1995-11-28
CA1277616C (en) 1990-12-11
ATE46718T1 (de) 1989-10-15
YU46597B (sh) 1994-01-20
SE8106641L (sv) 1982-06-24
FI79550B (fi) 1989-09-29
MY8700710A (en) 1987-12-31
KR830007825A (ko) 1983-11-07
GB2090258B (en) 1984-05-02
IL64243A (en) 1985-11-29
IL64243A0 (en) 1982-02-28
FR2493867A1 (fr) 1982-05-14
DOP1981004064A (es) 1988-03-16
DE3177106D1 (en) 1989-11-02
HK51685A (en) 1985-07-12
MC1424A1 (fr) 1982-10-18
SE460539B (sv) 1989-10-23
YU265681A (en) 1984-08-31
NO813785L (no) 1982-05-11
IT8124967A0 (it) 1981-11-10
GB2090258A (en) 1982-07-07
DK494681A (da) 1982-05-11
FR2493867B1 (fr) 1986-06-27
ZW26981A1 (en) 1982-06-02
EP0051873B1 (en) 1989-09-27

Similar Documents

Publication Publication Date Title
GB2090258B (en) Hybrid leukocyte interferon
SE8105657L (sv) Mikrobiell framstellning av humanfibroblastinterferon
HK49285A (en) Interferons and process for their preparation
FI90667C (fi) Menetelmä valmistaa uutta ihmisen tyypin I interferoniproteiinia
EP0072541A3 (en) Human leukocyte interferons, process for their microbial production, intermediates therefor and compositions containing them